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Pyrophosphatases (PPases) catalyze the hydrolysis of inorganic pyrophosphate generated in several cellular enzymatic reactions. A novel
human pyrophosphatase cDNA encoding a 334-amino-acid protein 60% identical to the previously identified human cytosolic PPase was cloned
and characterized. The novel enzyme, named PPase-2, was enzymatically active and catalyzed hydrolysis of pyrophosphate at a rate similar to that
of the previously identified PPase-1. A functional mitochondrial import signal sequence was identified in the N-terminus of PPase-2, which
targeted the enzyme to the mitochondrial matrix. The human pyrophosphatase 2 gene (PPase-2) was mapped to chromosome 4q25 and the 1.4-kb
mRNAwas ubiquitously expressed in human tissues, with highest levels in muscle, liver, and kidney. The yeast homologue of the mitochondrial
PPase-2 is required for mitochondrial DNA maintenance and yeast cells lacking the enzyme exhibit mitochondrial DNA depletion. We sequenced
the PPA2 gene in 13 patients with mitochondrial DNA depletion syndromes (MDS) of unknown cause to determine if mutations in the PPA2 gene
of these patients were associated with this disease. No pathogenic mutations were identified in the PPA2 gene of these patients and we found no
evidence that PPA2 gene mutations are a common cause of MDS in humans.
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enzymeIntroduction
Inorganic pyrophosphate is generated as a by-product in
several enzymatic reactions in cells. These reactions include
DNA and RNA synthesis, activation of fatty acids and amino
acids, as well as synthesis of the cyclic nucleotides cAMP and
cGMP [1,2]. Pyrophosphate cannot be exported efficiently
across the cell membrane and rapid intracellular hydrolysis of0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygeno.2005.09.017
Abbreviations: GFP, green fluorescent protein; GST, glutathione S-
transferase; PPi, inorganic pyrophosphate; PPase, pyrophosphatase; mtDNA,
mitochondrial DNA; MDS, mtDNA depletion syndrome.
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namic pull of the reactions. Pyrophosphatases (PPases)1 catalyze
the intracellular hydrolysis of pyrophosphate to inorganic
phosphate. A family of soluble PPases has been identified and
members of this enzyme family are present in both prokaryotic
and eukaryotic cells [1,3]. Escherichia coli contain one major
soluble PPase, which has been shown to be essential for cell
growth [4,5]. The yeast Saccharomyces cerevisiae contains two
sequence-related PPase genes: PPA1 and PPA2 [6,7]. The PPA1
gene encodes a cytosolic PPase that, similar to the E. coli PPase,
has been shown to be required for cell growth [7]. The yeast
PPA2 gene contains an N-terminal mitochondrial import signal
sequence and the enzyme is localized in the mitochondrial
matrix. The PPA2 gene product has been shown to be required
for mitochondrial DNA (mtDNA) maintenance. Yeast cells6) 410 – 416
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phenotype, with no detectable mtDNA, and require growth
medium that supports anaerobic metabolism [7].
In mammalian cells, both a soluble cytosolic and a mitochon-
drial PPase have been detected in biochemical studies [8–12].
Yang and co-workers purified a cytosolic PPase from bovine
retina and cloned the cDNA encoding the enzyme [12,13]. The
enzyme was shown to be sequence related to the family of
soluble PPase’s of yeast and bacteria. Recently, the cloning and
recombinant expression of the human homologue of the bovine
cytosolic PPase were reported [14,15]. Less is known about the
molecular properties of the mammalian mitochondrial PPase.
The enzyme is located in the mitochondrial matrix and bio-
chemical studies suggest that the enzymemay be associated with
mitochondrial inner membrane proteins such as components of
the respiratory chain [2,10,11]. Several different PPase-contain-
ing protein complexes with different molecular masses have
been purified from mammalian mitochondria, but it appears that
the catalytically active subunit in each complex has a size similar
to that of the yeast mitochondrial PPase [10,11].
The U0 phenotype of yeast cells lacking the mitochondrial
PPase suggests that deficiency in the expression of the human
mitochondrial PPase could result in mtDNA depletion.
Inherited mtDNA depletion syndromes (MDS) are a heteroge-
neous group of diseases that usually present with severe
symptoms of mitochondrial dysfunction in early childhood
[16,17]. For many of these patients the genetic defect causing
MDS remains undetermined. We cloned the cDNA and gene
encoding the human mitochondrial PPase to investigate the role
of this enzyme in mitochondrial pyrophosphate metabolism
and mtDNA maintenance. To investigate if PPase-2 is involved
in MDS in humans, we sequenced the PPA2 gene from patients
with MDS of unknown cause. In the present study, we report
the molecular characterization of the human mitochondrial
PPase and compare its properties to those of the human
cytosolic PPase. We also report the sequencing of the PPA2
gene from 13 patients with MDS.
Results
cDNA cloning of the human mitochondrial pyrophosphatase
We planned to clone the cDNA encoding the human
mitochondrial PPase based on sequence similarity to other
PPases. Two separate genes with a high level of sequence
similarity encode the yeast cytosolic and mitochondrial PPase.
We hypothesized that the human mitochondrial PPase would
exhibit sequence similarity to mammalian cytosolic PPases as
well as to the yeast enzymes. Since the cDNAs encoding the
human and bovine PPases have been cloned [17,18], we used the
predicted amino acid sequences of these enzymes to search the
GenBank expressed sequence tag database to identify human
cDNAs that encoded proteins similar, but not identical, to the
cytosolic PPase. Several cDNA clones that encoded a protein
60% identical to the cytosolic human PPase were identified.
The 1214-bp cDNA encoding this novel enzymewas completely
sequenced. The cDNA contained an open reading frame of 334amino acid residues corresponding to a protein with a predicted
molecular mass of 38 kDa (GenBank ID AF217187). We also
identified and resequenced the cDNA encoding the human cy-
tosolic PPase. This cDNA was 1204 bp and encoded a 289-
amino-acid protein with a molecular mass of 32.7 kDa (Gen-
Bank ID AF217186). Based on the high level of sequence
similarity, the novel enzyme was named PPase-2 and the pre-
viously cloned cytosolic enzyme was named PPase-1. Align-
ment of the predicted amino acid sequences of human PPase-1
and PPase-2 with the yeast cytosolic and mitochondrial PPases
showed that human PPase-2 was 60% identical to human
PPase-1 and 40–50% identical to the yeast enzymes at the
amino acid level (Fig. 1). Human PPase-2 was extended 31
amino acids at the N-terminus compared to human PPase-1.
This extension showed similarity to the N-terminal mitochon-
drial import signal of yeast PPase-2, suggesting that the human
PPase-2 protein was targeted to the mitochondria.
Expression and enzyme activity of human PPase-1 and PPase-2
Human PPase-1 and -2 were recombinantly expressed to
determine their enzymatic activity. The enzymes were
expressed as fusion proteins to GST to facilitate purification.
Both PPase-1 and PPase-2 were efficiently overexpressed and
purified to homogeneity by one-step glutathione affinity
chromatography with a yield of 3 mg pure recombinant
protein per liter bacterial culture. A factor Xa protease site was
incorporated between the PPase and GST in the expression
vector to allow separation of the two proteins after purification
by proteolytic cleavage. However, incubation of GST–PPase-2
with factor Xa resulted in nonspecific cleavage of the fusion
protein and loss of enzyme activity (data not shown).
Subsequent studies were therefore performed using the
uncleaved fusion proteins.
The rate of pyrophosphate hydrolysis was determined for
the purified recombinant fusion proteins. The reaction requires
the presence of three or four Mg2+ ions that bind the enzyme
and form a complex with the pyrophosphate [1,19]. The Mg2+
ion binding to the enzyme is concentration dependent and the
kinetic parameters of the enzyme reaction are accordingly
dependent on the Mg2+ ion concentration. The average
physiologic concentrations of free Mg2+ ions in the cytosol
and the mitochondria of human cells are similar, about 0.5 mM.
The total concentration of Mg inside a human cell is
approximately 20 mM, but most Mg is bound to proteins and
other substances, which is why the amount of free Mg2+ ions is
much lower. Considering the physiological conditions, we
chose to use 0.2–5 mM MgCl2 in reactions containing 10–200
AM pyrophosphate (Fig. 2). The data were fitted to Michaelis–
Menten plots. However, the method used for quantification of
inorganic phosphate produced in the reaction had a detection
limit of 1 AM and we were therefore not able to determine
accurately the initial rate kinetics for pyrophosphate concen-
trations <10 AM. The Km of PPase-1 is reported to be 1 AM
[13], but due to the limitations of the assay we were able to
state only that the Km of the recombinant PPase-1 was <10 AM.
The Km for PPase-2 pyrophosphate hydrolysis was 15 AM
Fig. 1. Alignment of human and yeast PPase-1 and PPase-2 predicted amino acid sequences. Black boxes indicate conserved amino acid residues compared to the
human PPase-2 sequence.
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Mg2+ ion concentrations (up to 20 mM) did not alter the kinetic
properties of PPase-2 compared to 5 mM (data not shown).
PPase activity is inhibited by Ca2+ ions and we compared theFig. 2. Pyrophosphate hydrolysis catalyzed by recombinant human (A) PPase-1
or (B) PPase-2 in 0.2 (o), 0.5 (.), 2 (g), or 5 mM (n) MgCl2. The
recombinant enzymes used in the assays were fused to GST at their N-terminus.sensitivity of PPase-1 and -2 to Ca2+ inhibition (Fig. 3). Both
enzymes were inhibited by Ca2+ ions with an IC50  10 AM.
However, there was no difference between the PPase-1 and the
PPase-2 sensitivity to Ca2+ inhibition.
PPA2 encodes an N-terminal mitochondrial import signal
The two yeast PPases that exhibit sequence similarity to both
human PPase-1 and PPase-2 differ in their subcellular location
[7]. The yeast PPase-1 is located in the cytosol, whereas the yeast
PPase-2 is located in the mitochondria. Alignment of the yeast
and human PPases showed that human PPase-2 has an N-
terminal extension similar to the extended N-terminus of the
yeast mitochondrial PPase (Fig. 1). This N-terminal extension
contains positively charged and hydrophobic amino acid
residues similar to a mitochondrial targeting signal. Subcellular
localization prediction using the PSORT algorithm also sug-
gested that the protein was targeted to the mitochondria [19].Fig. 3. CaCl2 inhibition of PPase-1- and PPase-2-catalyzed pyrophosphate
hydrolysis. 20 AM pyrophosphate and 0.5 mMMgCl2 were used in the reaction
and CaCl2 was added to the indicated concentrations.
Fig. 5. Northern blot analysis of PPase-1 and PPase-2 mRNA expression in
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cells to verify the mitochondrial localization of PPase-2 in
vivo (Fig. 4). Cells expressing PPase-1–GFP showed green
fluorescence in both the cytosol and the nucleus. However,
cells transfected with PPase-2–GFP did not exhibit any green
fluorescence. Several different plasmids that included differ-
ent parts of the untranslated 5V region were constructed, but
we were not able to detect expression of the full-length
enzyme in fusion with GFP (data not shown). We therefore
constructed a GFP fusion protein containing only the N-
terminal 31 aa of PPase-2 corresponding to the putative
mitochondrial import signal. This construct would allow
verification that the mitochondrial import signal was func-
tional, without introducing the full-length enzyme, which may
be toxic or poorly expressed in the cells. The HeLa cells
expressing the N-terminal region of PPase-2 in fusion with
GFP showed a dotted fluorescent pattern indicating mito-
chondrial targeting of the fusion protein. The mitochondrial
localization of the fluorescent protein was verified by
counterstaining the cells with the MitoTracker mitochondrial
dye.
Tissue expression pattern of human PPases
Northern blot analysis was used to determine the tissue
expression of PPase-1 and PPase-2 mRNA (Fig. 5). A major
mRNA transcript of 1.4 kb was detected in all 12
investigated tissues for both PPase-1 and PPase-2. The sizes
of these transcripts are consistent with the 1204- and 1214-bp
cDNAs. Compared to human PPase-1, the PPase-2 mRNAwas
expressed at higher relative levels in heart and skeletal muscle,
kidney, and liver. Analysis of the expression pattern based on
expressed sequence tag clones deposited in GenBank con-
firmed that mRNAs of both pyrophosphatase genes were
ubiquitously expressed in most tissues (data not shown).Fig. 4. Subcellular localization of PPase–GFP fusion proteins. The full-length PPase-1 protein or the N-terminal putative mitochondrial import signal of PPase-2 was
expressed in HeLa cells fused to GFP (left). The cells were counterstained with MitoTracker red to visualize the mitochondria (center). Overlay images of GFP and
MitoTracker fluorescence verified colocalization of the dyes in the cells transfected with PPase-2 (right).
human tissues. An actin probe was used as a hybridization control.
Fig. 6. Structure of the human PPA2 gene located at chromosome 4q25. Exons are shown as black boxes with roman numbers.
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The human genome sequence database was searched with
the human PPA2 cDNA to identify the corresponding genomic
sequence. Two bacterial artificial chromosome clones
(B35C18 and CTD-2006P5) containing the complete genomic
sequence corresponding to the human PPA2 cDNA were
identified. The genomic clones were located at chromosome
4q25. Alignment of the PPA2 cDNA with the genomic
sequence showed that the gene was divided into 12 exons
distributed over 100 kb (Fig. 6). The predicted ATG
translation start codon was located in the first exon.
SiRNA suppression of PPase-2 expression
To study the importance of PPase-2 for mtDNA integrity in
human cells we tried to silence the expression of PPase-2 by
single interference RNA. We transfected HeLa and osteosar-
coma cells with seven different plasmids containing siRNA
constructs and we selected for stable expression by using
neomycin. RNA from cells that had survived in the presence of
neomycin for 2 weeks or more was collected and reverse
transcribed before being subjected to SQ-PCR. Although seven
different constructs were tested, no decrease in PPase-2 mRNA
expression was detected in any cell line (data not shown).
Analysis of the PPA2 gene in MDS patients
Yeast cells lacking expression of mitochondrial PPase exhibit
mtDNA depletion. Therefore, based on analogies with other
MDS-related etiologies (dGK, TK2), we hypothesized that
mutations in PPA2 could be a cause of MDS in humans. The
coding sequences of the PPA2 genes from 13 patients with MDSTable 1
The designed primer pairs used for sequencing of the PPA2 gene in humans
Exon Forward primer (5V–3V)
1 GATGACTCCGGACGGTAGG
2 GGTCCTTAGATGGTGGCAAG
3 ACGAAGTGGGCATTTGGTAG
4 CGGGGGAAAACATCTAAGGT
5 TGGTGTTTCCTTTCCAAACA
6 TGGCCTTGGGCCTATGTAAT
7 GCAAGGCAGACTTTGGCTAT
8 CAGTCCAATGCTCTGCCACT
9 set A AAGCTTTGCCTGACTCTGGA
9 set B GGAGCTAGGCTTTTGCTCTTG
10 CTGGAGAGTGCTTTGCTGTG
11 TCAGGTTAGAGATCCATTGTGTG
12 TTGGGACGAAAGTTTGAAGGwere sequenced. The locations of gene regulatory elements for
the PPA2 gene are not yet identified and the sequencing was
therefore limited to the coding region of the gene. The 12 exons
containing the open reading frame were PCR amplified by
primers flanking the exons (Table 1). No pathogenic mutations
were identified among these patients; however, four polymorph-
isms were found. In one patient exon 1 had a silent heterozygous
change, C to T, at nucleotide 41 (mRNA AF217187) at amino
acid 9 (arginine). This polymorphism has been reported at the
NCBI SNP database. In another patient exon 1 had a
heterozygous change, A to G transition, at nucleotide 78
(mRNA AF217187), which changes amino acid 22 from
threonine to alanine. In addition, this patient has a heterozygous
change, C to G, in intron 5 at the 5th nucleotide after exon 5. In
8 patients, exon 9 showed a G-to-C transversion at nucleotide
846, which changes amino acid 282 from lysine to asparagine.
The transversion is homozygous in 6 of these patients, while in
the other 2 patients the change is heterozygous. This polymor-
phism is also listed in the NCBI SNP database. In 3 of these
patients a change in intron 8 was also seen, IVS8–19 (TTTG)2,
whereas the normal sequence is IVS8–19 (TTTG)3. These
alterations were, however, also seen in 4 of the 5 controls and are
therefore considered neutral polymorphisms. In summary, no
mutations in the PPA2 gene were identified in these patients that
suggest a role for PPase-2 deficiency in MDS.
Discussion
We have identified and cloned the cDNA of a novel human
PPase and showed that the enzyme contains a functional N-
terminal mitochondrial import signal. Although the biochem-
ical properties of mammalian mitochondrial PPase have been
studied on enzyme purified from tissues, the cloning of theReverse primer (5V–3V)
GGAAGTAAGGTGGCCTGGAC
CCTTTCAAGGTGCTTCCAAA
ACATCGGAATGCACATGAAA
ATGCCAAACAACTTGCAACA
CCAAATGACATGTCCTCAGAA
AGGTGTTAGGCTGGCTTTGA
AACTCCCCTATGTGAACTTCTTTT
TTCAGCCTTGTTGATTCACTT
AAAATGCAAAAATCTGAAATCTG
TCTTACCAATTTATAGCTCCTCCA
TGCTTCTCAAAAGGACTTGACA
TCACCGTACAATCAAATCATTTTC
GGCTGGTCTTGAACTCCTGA
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We found that the human cytosolic and mitochondrial PPases
were both ubiquitously expressed in human tissues. The
mitochondrial PPase-2 was expressed at highest levels in
tissues rich in mitochondria, such as muscle, liver, and kidney.
The ubiquitous expression of the human PPases suggests that
these enzymes, similar to their microbial homologues, are
involved in the ‘‘housekeeping’’ degradation of pyrophosphate
generated by different cellular metabolic processes.
Inherited MDS are rare and usually severe diseases that often
present in infancy or early childhood [16,17]. The symptoms of
these disorders are related to mitochondrial dysfunction and
decreased oxidative phosphorylation. The organs most affected
are highly dependent on aerobic metabolism, such as muscle,
liver, and brain. However, there is wide tissue specificity among
MDS patients, likely associated with different genetic etiologies.
Recently, mutations in the mitochondrial deoxyribonucleoside
kinases, deoxyguanosine kinase, and thymidine kinase 2 have
been identified in some patients with mtDNA depletion [20,21].
However, subsequent studies suggest that mutations in these
genes account for only a minority of MDS cases and that other
genetic defects are responsible for the syndrome in the majority
of patients [22]. The importance of the yeast mitochondrial
PPase in mtDNA maintenance suggests that the human PPase-2
also may be required for normal mtDNA integrity and patients
with mtDNA depletion syndrome of unknown cause were
therefore screened for mutations in the PPA2 gene. However, no
pathogenic mutations were identified in the PPA2 gene of the 13
MDS patients studied. Although we found no evidence in the
investigated patients that PPA2 gene mutations are likely to be a
common cause of MDS in humans, additional patients with
MDS are being investigated for PPA2 gene mutations. Accord-
ingly, identification of further genes needed for mtDNA
maintenance might pinpoint a major gene causing MDS.
Materials and methods
cDNA cloning and expression of human pyrophosphatases
The GenBank expressed sequence tag database at the National Institute for
Biotechnology information (http://www.ncbi.nlm.nih.gov/) was searched with
the Basic Local Alignment Search Tool (BLAST) [23] to identify human
expressed sequence tag cDNA sequences that encoded proteins similar to the
bovine cytosolic and yeast mitochondrial PPase [7,13]. The expressed sequence
tag clones identified were generated by the IMAGE Consortium and obtained
from Research Genetics (IMAGE ID 5193749 and 5205378) [24]. The DNA
sequences of the plasmids were determined using an ABI310 automated DNA
sequencer (Perkin–Elmer, Applied Biosystems).
We expressed the two human inorganic pyrophosphatases in E. coli fused to
glutathione S-transferase. Oligonucleotide primers that flanked the open reading
frame of the cDNAs were designed with BamHI and XhoI restriction enzyme sites
(PPA1: 5V-GGGATCCATATGAGCGGCTTCAGCACCGAGGAGCG and 5V-
AACTCGAGTTAGTTTTTCTGGTGATGGAACCACT; PPA2, 5V-GGGATCCA-
TATGGCCCTGTACCACACTGAGGAGCG and 5V-AACTCGAGTCACTTGC-
CAAGGAAGTGCCAC). The oligonucleotides were used in a PCR and the
amplified DNA fragment was cloned in the BamHI–XhoI sites of the pGEX-5X-1
plasmid vector (Amersham Biotech).
The plasmids were transformed into the E. coli strain BL21(DE3)pLysS
(Stratagene). Protein expression was induced at OD600 0.7 with 1 mM IPTG for
3 h at 37-C. The recombinant proteins were purified from crude bacterial
extracts using glutathione affinity chromatography on glutathione-4B Sephar-ose (Amersham Pharmacia Biotech). The purified recombinant proteins were
eluted in 50 mM Tris, pH 8.0, 250 mM NaCl, and 10 mM reduced glutathione
(Sigma). The size and purity of the recombinant proteins were determined by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Phast system;
Amersham Biotech). The protein concentrations were determined with the
Bradford Protein Assay (Bio-Rad) and bovine serum albumin was used as the
concentration standard.
Enzyme assays
Hydrolysis of pyrophosphate (Sigma) was determined in 160 Al reaction
buffer containing 50 mM Tris, pH 8.0, 0.1 mM EGTA, and indicated concen-
trations of MgCl2. One to ten nanograms of recombinant PPase was added and
the reactions were incubated 10 min at 22-C. Formation of inorganic phosphate
was determined using a malachite green colorimetric assay [25,26]. Forty
microliters of the malachite green assay mixture containing 1.3 AM malachite
green, 3% (w/v) ammonium molybdate, 0.2% (v/v) Tween 20 dissolved in 2 M
H2SO4 was added to terminate the enzyme reactions. The absorbance at 620 nm
was determined and compared to a NaH2PO4 concentration standard. The data
were analyzed and fitted to Michaelis–Menten plots using Statistica (StatSoft).
Subcellular localization
We used the pEGFP-N1 vector (Clontech) to express the human PPases fused
to the green fluorescent protein in HeLa cells (American type culture collection).
Oligonucleotides containingHindIII and BamHI restriction enzyme sites (PPA1,
5V-TAAGCTTTCCGGCACTATGAGCGGCTTCAGCACC and 5V-TTGGAT-
CCTTTTTCTGGTGATGGAACCACTTATC; PPA2, 5V-CGAAGCTTGTG-
TATGCTGAGCCGCTGCCGCA and 5V-ATGTCGACCAGCCTTCCTTGTCQ
AAAAATCT) were used to clone the open reading frame of the cDNAs into the
HindIII –BamHI sites of the pEGFP-N1 vector. The HeLa cells were cultured in
Dulbecco’s MEM modified medium supplemented with 10% fetal calf serum,
100 U/ml penicillin, and 0.1 mg/ml streptomycin. The plasmid was transfected
with FuGENE (Boehringer Mannheim). The cells were counterstained with
MitoTracker red (Molecular Probes). Microscopy was performed on a Nikon
Eclipse E600 microscope equipped with a SPOT RT digital camera.
Northern blot expression analysis
A human multiple-tissue Northern blot containing poly(A) RNA from 12
human tissues was obtained from Clontech. DNA fragments comprising bp 1–
895 of PPase-1 and bp 1–1002 of PPase-2 was PCR amplified and labeled with
[a-32P]dCTP (3000 Ci/mmol; Amersham Biotech) using the Prime-A-Gene
random labeling kit (Promega). The probe was purified by spin chromatography
on ChromaSpin TE-100 (Clontech) and hybridized to the Northern blot filter in
ExpressHyb hybridization solution (Clontech) at 68-C for 1 h. The filter was
washed as described in the manufacturer’s protocol and exposed to phosphoima-
ging plates. Human actin cDNAwas used as a control probe (Clontech).
SiRNA analysis
Seven different plasmids that contained DNA templates for the synthesis of
siRNAs under the control of the H1 promoter were generated using the
pSilencer3.1-H1neo vector (Ambion). The selection of the coding sequences for
the siRNA was determined using the siRNA target finder tool available on
Ambion’s home page (http://www.ambion.com). The sequences were analyzed
by BLAST to ensure they had no significant sequence homology with other
genes. Seven top-strand and seven bottom-strand oligos were ordered from TAG
Copenhagen (the sequences are available by e-mail: magnus.johansson@
mbb.ki.se) and used in the making of the plasmids according to the protocol.
The generated plasmids were transfected into HeLa and osteosarcoma cells. The
cells were cultured in Dulbecco’s MEM modified medium supplemented with
10% fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 110 Ag/ml
sodium pyruvate, and 50 Ag/ml uridine [27]. After 2 weeks of selection with
neomycin, RNA from the cells was extracted using Trizol. The RNAwas reverse
transcribed (Invitrogen) and the resulting cDNA was subjected to semiquanti-
tative PCR (PPase-2, forward 5V-AGCCAATGAATCCCATTAAACAA-3V and
S. Curbo et al. / Genomics 87 (2006) 410–416416reverse 5V-TCCAAAGCAGTTCGTGCTCTT-3V; actin, forward: 5V-TCCTCCT-
GAGCGCAAGTACTC-3V and reverse 5V-GCATTTGCGGTGGACGAT-3V).
The PCR products were analyzed by gel electrophoresis.
Patient evaluations
At Columbia University College of Physicians and Surgeons in the United
States, the patient samples were collected under Institutional Review Board
(IRB)-approved protocols. Blood was collected for DNA analysis with an IRB
consent form while muscle samples were studied under an IRB exemption
protocol. Of the seven patients from Columbia, four had the myopathic form of
MDS, two had the hepatic form, and the clinical feature of the last patient is still
undetermined. All of the patients with myopathy were screened for TK2
mutations (MIM 188250), while both patients with hepatopathies were
screened for dGK mutations (MIM 601465). The diagnosis of MDS was made
by Southern blot analyses, which revealed <30% mtDNA in affected tissues
relative to controls. At the Children’s Hospital in Rome, Italy, the patient
samples were collected after approval of the IRB. Of the six patients
investigated in Rome, two had hepatopathy and significant involvement of
the central nervous system, one had heart muscle involvement as the only
clinical feature, and three patients had different degrees of myopathy, in some
cases associated with encephalopathy. The level of mtDNA reduction in these
patients varied from 42 to 95%. All the patients that were screened in Rome had
also been sequenced for dGK (MIM 601465), TK2 (MIM 188250), the
mitochondrial deoxynucleotide carrier (MIM 606521), and the 5V-deoxyribo-
nucleotidase (MIM 605292). No mutations were detected.
Mutation analysis
Genomic DNA from patients with MDS was obtained as described [28].
PCR amplifications and DNA sequencing of PPase-2 were performed using
intronic primers listed in Table 1. The PCRs were performed under standard
conditions using 1.5 mMMgCl2, 0.2 mM dNTP, 0.2 AM each primer, 100–200
ng DNA, and Taq polymerase (Roche). The amplification was done using a
thermocycler (Applied Biosystems GeneAmp PCR System 7900) set at an
initial denaturing step at 94-C for 5 min, followed by 30–35 cycles of 30 s at
94-C, 30 s at 59–60-C, and 30 s at 72-C, and in the end 5 min of extension at
72-C. Four exons required special conditions for amplification. Exon 1 was
amplified by touchdown PCR from 70 to 60-C (annealing) and including 4
Al DMSO and Taq Platinum (Invitrogen) in the PCR. DMSO was used in the
reaction of exon 6. To read the coding region of exon 9 in some individuals that
showed intronic rearrangements, it was necessary to combine primer sets A and
B. For the amplification of exon 12, touchdown PCR from 70 to 60-C
(annealing) was used. The DNA sequencing of the PCR products was
performed using the BigDye Terminator kit and the ABI Prism 310 system.
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